Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Tectonic Therapeutic, Inc. Common Stock

TECX

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Last trade $20.00
Day change -$0.98 (-4.67%)
Day range $19.87 – $21.42
Volume 103,293
Market cap $410M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$410.15M
Price / earnings
—
Price / book
1.79×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.84×

Profitability

Earnings per share
-$4.51
Return on assets
-36.13%
Return on equity
-38.42%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
19.71×
Quick ratio
19.71×
Cash ratio
19.39×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$69.33M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TECX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$6.02M$6.17M$6.43M$5.18M$4.96M$5.15M$5.26M$4.84M
Research and development$17.44M$18.05M$20.87M$16.34M$16.93M$17.19M$13.04M$9.16M
Total operating expenses$23.46M$24.22M$27.3M$21.52M$21.89M$22.33M$18.3M$13.99M
Operating income-$23.46M-$24.22M-$27.3M-$21.52M-$21.89M-$22.33M-$18.3M-$13.99M
Interest expense-$4K-$6K-$8K-$12K-$14K-$17K-$20K-$22K
Income before taxes-$21.35M-$22.21M-$25.24M-$18.97M-$19.04M-$19.01M-$15.91M-$12.37M
Income taxes$0$77K$0$254K$0$976K$0$0
Net income-$21.35M-$22.29M-$25.24M-$19.23M-$19.04M-$19.98M-$15.91M-$12.37M
Net income attributable to common shareholders-$21.35M-$22.29M-$25.24M-$19.23M-$19.04M-$19.98M-$15.91M-$12.37M
EBITDA-$23.21M-$23.93M-$27M-$21.18M-$21.55M-$21.99M-$17.94M-$13.48M
Basic earnings per share-$1.08-$1.18-$1.34-$1.03-$1.02-$1.07-$0.93-$0.83
Diluted earnings per share-$1.08-$1.18-$1.34-$1.03-$1.02-$1.07-$0.93-$0.83

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Tectonic (TECX) Q2 R&D Soars 142%

Biotechnology company Tectonic Therapeutic reported a wider Q2 2025 net loss of $20.0 million, driven by increased clinical trial activities for its lead drug TX45 targeting pulmonary hypertension. Despite higher expenses, the company maintains a strong cash position of $287.4 million, with runway projected into Q4 2028.

GlobeNewswire Inc.

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

Tectonic Therapeutic announced positive results from a Phase 1b clinical trial of its lead asset TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF). The data confirmed TX45's tolerability and showed improvements in left ventricular function and pulmonary hemodynamics.

GlobeNewswire Inc.

Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45

Tectonic Therapeutic announced favorable Phase 1a results for its lead program TX45, a long-acting relaxin fusion protein, in the treatment of Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The results showed TX45 was well-tolerated with no observed immunogenicity and demonstrated a favorable PK/PD relationship, allowing for the identification of doses for the Phase 2 clinical trial.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.